Results of a Dutch Phase Ii trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer
Debruyne, F.M.; Karthaus, H.F.; Schröder, F.H.; de Voogt, H.J.; de Jong, F.H.; Klijn, J.G.
Progress in Clinical and Biological Research 185a: 251-270
1985
ISSN/ISBN: 0361-7742 PMID: 3929265 Document Number: 250468
Document emailed within 1 workday
Related Documents
De Voogt, H.J.; Adenauer, H.; Widdra, W.G. 1991: The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. a 10-year review on 1522 patients treated in 119 centres on 4 continents Scandinavian Journal of Urology and Nephrology. Supplementum 138: 131-136Okuda, K.; Ushiroyama, T.; Yoshikawa, M.; Sugimoto, O. 1988: Effect of LHRH agonist (buserelin) on pulsatile secretion of LHRH and LH Nihon Sanka Fujinka Gakkai Zasshi 40(12): 1889-1893
Muthalib, A.; Darwis, I.; Prayogo, N.; Sutjipto 2000: Preliminary results of multicenter phase Ii trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 498-504
Wenderoth, U.K.; Jacobi, G.H. 1986: Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin Annales d'Urologie 20(2): 95-97
Yamaguchi, Y.; Minami, K.; Kawabuchi, Y.; Emi, M. 2006: A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer Hepato-Gastroenterology 53(68): 201-205
Gravis, G.; Mousseau, M.; Douillard, J.Y.; Dorval, T.; Fabbro, M.; Escudier, B.; Mignot, L.; Viens, P. 2001: Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial European Cytokine Network 12(2): 239-243
Steg, A.; Chiche, R.; Boccon-Gibod, L.; Debré, B.; Duchier, J.; Schally, A.V. 1984: Treatment of prostatic cancer with an LH-RH agonist: the D Trp6 LH-RH. Preliminary results in 30 cases Annales d'Urologie 18(6): 388-392
Kuber, W.; Treu, T.; Kratzik, C.; Girsch, E.; Zeillinger, R.; Spona, J. 1990: Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies Wiener Klinische Wochenschrift 102(21): 640-647
Lück, H.J.; Thomssen, C.; du Bois, A.; Lisboa, B.W.; Untch, M.; Kühnle, H.; Jänicke, F.; Meerpohl, H.G.; Lindner, C.; Konecny, G.; Hecker, D.; Diergarten, K. 1997: Preliminary results of a phase Ii study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer Seminars in Oncology 24(1 Suppl 3: S13-S16
Arai, Y.; Kido, C.; Endo, T.; Aoki, T. 1987: Preliminary results of a phase Ii study of 5-FU, adriamycin, and mitomycin C (FAM) in combined hepatic infusion in patients with non-resectable metastatic liver cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(7): 2327-2333
Nicholson, B.; Paul, D.; Shyr, Y.; Garrett, M.; Hande, K.R.; Johnson, D.H. 1997: Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase Ii trial Seminars in Oncology 24(4 Suppl 11: S11
Carpenter, J.T.; Raney, M.; Logan, T. 1986: Phase Ii evaluation of procarbazine in metastatic breast cancer: a Southeastern Cancer Study Group Trial Cancer Treatment Reports 70(5): 679-680
Arimura, A.; Talbot, S.; Serafini, P.C.; Schally, A.V. 1980: Sites of paradoxical action of the LHRH agonist (D-Trp6)-LHRH International Journal of Fertility 25(3): 151-156
Garin, A.M.; Gorbunova, V.A.; Bychkov, M.B.; Mindra, N.V.; Stenina, M.B.; Topchieva, S.V.; Treshchalina, E.M.; Chitiia, L.V.; Sdvizhkov, A.M.; Borisov, V.I.; Gurov, S.N.; Gershanovich, M.L.; Makhnova, E.V.; Nebol'sin, V.E. 2004: Results of a multicenter, phase-Ii clinical trial of Dicarbamin used to shield leukopoiesis in cancer patients with immunosuppression due to chemotherapy Voprosy Onkologii 50(2): 184-188
Wanderley, M.I.; Negro-Vilar, A. 1996: Pretreatment with phorbol ester and an LHRH agonist reduces testosterone production and protein kinase C activity in rat Leydig cells challenged with PDBu and LHRH Brazilian Journal of Medical and Biological Research 29(11): 1557-1565
Medina, W.; Kirkwood, J.M. 1982: Phase Ii trial of mitolactol in patients with metastatic melanoma Cancer Treatment Reports 66(1): 195-196
Labrie, F.; Dupont, A.; Giguère, M.; Borsanyi, J.P.; Lacourciere, Y.; Bélanger, A.; Lachance, R.; Emond, J.; Monfette, G. 1988: Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer Progress in Clinical and Biological Research 260: 41-62
St-Arnaud, R.; Lachance, R.; Dupont, A.; Labrie, F. 1986: Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate Clinical and Investigative Medicine. Medecine Clinique et Experimentale 9(4): 215-221
Abbou, C.C.; Lucas, C.; Leblanc, V. 1997: Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(6): 984-995
Olsson, J.O. 1990: Orchiectomy or LHRH analogues in prostatic cancer? Lakartidningen 87(4): 190